Assurex Health announces discharge of new psychiatric pharmacogenomic test panel Today announced the discharge of GeneSight Psychotropic 2 Assurex Health information-om-finasterid.html www.propeciasverige.com .0, its lead psychiatric pharmacogenomic test panel.0 report includes information for 17 psychotropic medications which have pharmacogenomic information within their FDA approved labels. Related StoriesDisclosing genetic risk for CHD results in lower low-density lipoprotein cholesterolBerkeley Lab scientists identify genetic elements that impact neurological disorders and body weightResearchers discover better genetic diversity among malignancy cells than anticipated Assurex Health is committed to bringing the latest clinical and scientific results to support clinicians and their patients in selecting medicines to treat neuropsychiatric disorders, according to Bryan M.
, a leading biotechnology firm in the emerging field of regenerative medicine, today announced today that it offers priced an underwritten open public offering of its common share at a price of $3.90 per share. Concurrently, the business entered into a private placement for the sale of common share at the same cost as the underwritten public providing. Gross proceeds to the Company from the public offering and the private placement are anticipated to be approximately $5.5 million in the aggregate. Closing of the general public offering is scheduled for February 10, 2015 at the mercy of customary closing conditions. THE BUSINESS intends to utilize the net proceeds from the public offering for continued advancement of product applicants through scientific trials and for operating capital and general corporate reasons.